Nektar Therapeutics (NASDAQ: NKTR) is -29.14% lower on its value in year-to-date trading and has touched a low of $0.64 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NKTR stock was last observed hovering at around $0.64 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $0.66, the stock is -19.17% and -20.63% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.56 million and changing 3.40% at the moment leaves the stock -40.51% off its SMA200. NKTR registered -27.11% loss for a year compared to 6-month loss of -49.31%. The firm has a 50-day simple moving average (SMA 50) of $0.8306 and a 200-day simple moving average (SMA200) of $1.10795.
The stock witnessed a -21.90% gain in the last 1 month and extending the period to 3 months gives it a -30.19%, and is -17.79% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.53% over the week and 8.83% over the month.
Nektar Therapeutics (NKTR) has around 61 employees, a market worth around $122.64M and $98.43M in sales. Profit margin for the company is -120.86%. Distance from 52-week low is 3.40% and -65.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.58%).
The EPS is expected to shrink by -8.51% this year
181.0 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 72.83% of the company’s shares. The shares outstanding are 185.78M, and float is at 179.37M with Short Float at 3.87%. Institutions hold 71.91% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $22.17 million. The investor’s holdings represent 8.5599 of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $18.79 million to account for 7.2575 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.6587 and valued at over $16.08 million, while SAMLYN CAPITAL, LLC holds 4.529 of the shares totaling 9.46 million with a market value of $11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Zalevsky Jonathan, the company’s Chief R&D Officer. SEC filings show that Zalevsky Jonathan sold 10,300 shares of the company’s common stock on Feb 19 ’25 at a price of $1.01 per share for a total of $10403.0. Following the sale, the insider now owns 0.32 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Feb 19 ’25 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 11,040 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $1.01 per share for $11150.0. Following the transaction, the insider now directly holds 0.32 million shares of the NKTR stock.
Still, SEC filings show that on Feb 19 ’25, ROBIN HOWARD W (President & CEO) disposed off 23,774 shares at an average price of $1.01 for $24012.0. The insider now directly holds 1,086,901 shares of Nektar Therapeutics (NKTR).
